2026 WCLC即将来袭！一文速览OA＋MA专场180+重磅研究

摘要号：OA01.01

标题：In-Vivo Bronchoscopic FLIM Imaging Enables Optical Confirmation and Sampling of Peripheral Lung Lesions: First-in-Human Prospective Study

中文标题：体内支气管镜荧光寿命成像（FLIM）实现肺外周病变的光学确认与取样：首次人体前瞻性研究

讲者：Adam Marshall (Edinburgh, United Kingdom)

摘要号：OA01.02

标题：European Real-World Experience With Robotic-Assisted Bronchoscopy and Integrated Cone-Beam CT: Results From the Eurorab Group

中文标题：机器人辅助支气管镜联合锥形束CT的欧洲真实世界经验：EuroRAB协作组结果

讲者：ANTONI ROSELL (Badalona, Spain)

摘要号：OA01.03

标题：Distinguishing Multiple Primary Lung Cancers From Intrapulmonary Oligometastasis Using Whole Genome Sequencing

中文标题：全基因组测序鉴别多原发肺癌与肺内寡转移

讲者：Taekeun Park (Seoul, Korea)

摘要号：OA01.04

标题：Survival Outcomes and Risk Factors for Nodal Upstaging in Clinical Node-Negative NSCLC From a Population-Based Cohort

中文标题：基于人群队列的临床淋巴结阴性NSCLC淋巴结升期的生存结局与危险因素

讲者：Jessica Rice (Memphis, United States of America)

摘要号：OA02.01

标题：Efficacy and Safety of GFH375 in Advanced KRASG12D Mutant Non-Small Cell Lung Cancer (NSCLC) Patients

中文标题：GFH375治疗晚期KRAS G12D突变型NSCLC的疗效与安全性

讲者：李子明 (上海交通大学附属胸科医院)

摘要号：OA03.01

标题：Socioenvironmental Determinants of Health and Associations With Sybil AI Risk Scores.

中文标题：社会环境健康决定因素及其与Sybil人工智能风险评分的关联

讲者：Evan Garrad (Chicago, United States of America)

摘要号：OA03.02

标题：Breathomics-Based Risk Stratification for Pre-imaging Triage of Lung Cancer: A Prospective Multicenter Study

中文标题：基于呼气组学的肺癌影像检查前分诊风险分层：前瞻性多中心研究

讲者：郑健琪 (广州医科大学附属第一医院)

摘要号：OA03.03

标题：Improving Engagement With Australia’s National Lung Cancer Screening Program: The Ready to Screen Cluster Randomised Implementation Trial

中文标题：提高澳大利亚国家肺癌筛查项目参与度：Ready to Screen整群随机实施试验

讲者：Nicole Rankin (Melbourne, Australia)

摘要号：OA04.01

标题：A Phase III Randomized Multicenter Trial of Adjuvant Gefitinib Plus Chemotherapy Versus Chemotherapy in EGFR-Mutant NSCLC

中文标题：辅助吉非替尼联合化疗对比单纯化疗治疗EGFR突变型NSCLC的III期随机多中心试验

讲者：Beung-Chul Ahn (Goyang-si, Korea)

摘要号：OA04.02

标题：Final Analysis of the Phase 3 IMpower030 Study: Perioperative Atezolizumab + Chemotherapy in Resectable Stage II-IIIB NSCLC

中文标题：III期IMpower030研究最终分析：围手术期阿替利珠单抗联合化疗治疗可切除II–IIIB期NSCLC

讲者：Benjamin Solomon (Australia)

摘要号：OA04.03

标题：Neoadjuvant Divarasib Shows Manageable Safety and Promising Activity in Resectable KRAS G12C+ NSCLC: Updated NAUTIKA1 Data

中文标题：新辅助Divarasib治疗可切除KRAS G12C阳性NSCLC安全性可控且活性可期：NAUTIKA1更新数据

讲者：Jamie Chaft (New York, United States of America)

摘要号：OA05.01

标题：Phase 1 Study of LB2102, a dnTGFBR2-armored DLL3-targeted Autologous CAR-T Cell Therapy, in Subjects With Relapsed or Refractory SCLC or LCNEC

中文标题：dnTGFβR2装甲的DLL3靶向自体CAR-T细胞疗法LB2102治疗复发/难治SCLC或大细胞神经内分泌癌的I期研究

讲者：Alberto Chiappori (Tampa, United States of America)

摘要号：OA05.02

标题：Epigenetic Dysregulation Permits E2F1 Activation-Mediated Neuroendocrine Transformation inEGFR-Mutant Lung Adenocarcinoma

中文标题：表观遗传失调允许E2F1激活介导EGFR突变型肺腺癌的神经内分泌转化

讲者：Zhijun Xia (江苏省肿瘤医院)

摘要号：OA06.01

标题：Low-Grade Doesn’t Mean Low Impact: Patient-Reported Diarrhea and Quality of Life in Lung Cancer

中文标题：低级别≠低影响：肺癌患者报告的腹泻与生活质量

讲者：Bellinda King-Kallimanis (Tarpon Springs, United States of America)

摘要号：OA06.02

标题：The Effect of Oncology Nurse-Led Discharge Planning on Health Outcomes in Lung Cancer Survivors: A Randomized Controlled Trial

中文标题：肿瘤专科护士主导的出院计划对肺癌生存者健康结局的影响：随机对照试验

讲者：Xi Zhou (重庆大学附属肿瘤医院)

摘要号：OA06.03

标题：Public Perceptions of Lung Cancer: Stigma, Symptom Awareness and Screening Attitudes - Findings From a 2026 Global Survey

中文标题：公众对肺癌的认知：污名化、症状知晓与筛查态度——2026年全球调查结果

讲者：Jesme Fox (Liverpool, United Kingdom)

摘要号：OA06.04

标题：Trajectories and Influencing Factors of Perceived Return-To-Work Barriers in Patients After Lung Cancer Surgery: A Longitudinal Cohort Study

中文标题：肺癌术后患者重返工作岗位障碍感知的变化轨迹及影响因素：纵向队列研究

讲者：Cheng Lei (四川省肿瘤医院)

摘要号：OA07.01

标题：Ambient Air Pollution Exposure and Risk of Pleural Mesothelioma: A Prospective Analysis of the UK Biobank

中文标题：环境空气污染暴露与胸膜间皮瘤风险：英国生物银行（UK Biobank）前瞻性分析

讲者：崔久嵬 (吉林大学第一医院)

摘要号：OA07.02

标题：Cytisine for Smoking Cessation in Older Adults: Evidence From the RISP Trial

中文标题：金雀花碱用于老年人戒烟：RISP试验证据

讲者：Massimiliano Cani (Milan, Italy)

摘要号：OA07.03

标题：Ambient Air Pollution Exposure and Lung Cancer Prognosis - Pooled and Comparative Analysis of the International Lung Cancer Consortium

中文标题：环境空气污染暴露与肺癌预后：国际肺癌联盟汇总与比较分析

讲者：Rayjean Hung (Toronto, Canada)

摘要号：OA07.04

标题：Implementation Strategies to Embed Smoking Cessation Support in Lung Cancer Screening: An International Expert Survey

中文标题：将戒烟支持嵌入肺癌筛查的实施策略：国际专家调查

讲者：Nathan Harrison (Adelaide, Australia)

摘要号：OA08.01

标题：CT-guided Microwave Ablation vs Lobectomy for Hilar GGO-predominant Nodules: Prospective Multicenter Non-Inferiority Study

中文标题：CT引导下微波消融对比肺叶切除治疗肺门区磨玻璃为主结节：前瞻性多中心非劣效研究

讲者：刘王睿 (上海交通大学医学院附属仁济医院)

摘要号：OA08.02

标题：Non-Invasive Prediction of Spread Through Air Spaces in Stage I Lung Adenocarcinoma Using CT-based Virtual PET (CPT-STAS): A Multicenter Study

中文标题：基于CT虚拟PET（CPT-STAS）无创预测I期肺腺癌气腔播散：多中心研究

讲者：Maotao Weng (广州中医药大学)

摘要号：OA08.03

标题：Bayesian STAS Prediction for Segmentectomy Planning: Smooth Contour and Nodal Status as Dominant Predictors

中文标题：用于肺段切除规划的贝叶斯STAS预测：光滑轮廓与淋巴结状态为主要预测因子

讲者：Seyda Ors (Izmir, Turkey)

摘要号：OA09.01

标题：Effect of Thymosin a-1 on Treatment Completion and Pneumonitis in Chemoradiation Plus Immunotherapy for LA-NSCLC: A Randomized Phase II Trial

中文标题：胸腺法新对局部晚期NSCLC放化疗联合免疫治疗完成率及肺炎的影响：随机II期试验

讲者：邱波 (中山大学肿瘤防治中心)

摘要号：OA09.02

标题：ASTRES: A Phase 2, Single-Arm Study of Atezolizumab in Locally Advanced, Unresectable, Stage III, Non-Small Cell Lung Cancer

中文标题：ASTRES：阿替利珠单抗治疗局部晚期不可切除III期NSCLC的II期单臂研究

讲者：Enriqueta Felip (Spain)

摘要号：OA09.03

标题：A Phase 2 Study of JS207, a PD-1/VEGF Bispecific Antibody, Plus Chemotherapy in Patients With Unresectable Stag III NSCLC

中文标题：PD-1/VEGF双特异性抗体JS207联合化疗治疗不可切除III期NSCLC的II期研究

讲者：吴一龙 (广东省人民医院)

摘要号：OA09.04

标题：Stereotactic Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer Unfit for Concurrent Chemoradiation: The STARLORD Study

中文标题：不适合同步放化疗的局部晚期NSCLC的立体定向放疗：STARLORD研究

讲者：Francesco Cuccia (Palermo, Italy)

摘要号：OA10.01

标题：Phase 1 Global Study of Iza-Bren in Patients With Metastatic EGFR-mutated NSCLC: Results of the Randomized Dose Expansion Cohort

中文标题：Iza-Bren治疗转移性EGFR突变型NSCLC的全球I期研究：随机剂量扩展队列结果

讲者：Alexander Spira (Faifax, United States of America)

摘要号：OA10.02

标题：Phase II Study of SYS6010 Plus Enlonstobart in Actionable Genomic Alteration (AGA)-Negative Advanced Non-Small Cell Lung Cancer (Ansclc)

中文标题：SYS6010联合Enlonstobart治疗驱动基因阴性晚期NSCLC的II期研究

讲者：李玮 (上海市东方医院)

摘要号：OA11.01

标题：Multi-Omics of ctDNA Shedding Defines Ctnmb Staging and TME Heterogeneity in Early-Stage Lung Cancer

中文标题：ctDNA释放的多组学分析界定早期肺癌的TNM-B分期与肿瘤微环境异质性

讲者：Zifan Li (北京大学人民医院)

摘要号：OA11.02

标题：Prioritizing Circulating Proteins for Lung Cancer Risk Stratification Through Integrated Evidence

中文标题：基于整合证据优选用于肺癌风险分层的循环蛋白

讲者：吕章艳 (天津医科大学肿瘤医院)

摘要号：OA11.03

标题：Predicting NSCLC Neoadjuvant Immunotherapy Response Using H&E-Derived T-Cell States via Deep Learning

中文标题：基于深度学习利用H&E图像衍生的T细胞状态预测NSCLC新辅助免疫治疗应答

讲者：Dongshen Li (广东省人民医院)

摘要号：OA11.04

标题：Explainable Machine Learning Model to Predict High-Grade Adverse Events in Neoadjuvant Chemo-Immunotherapy for NSCLC: A Multicenter Study

中文标题：预测NSCLC新辅助化疗免疫治疗高级别不良事件的可解释机器学习模型：多中心研究

讲者：Fei-Hang Zhi (上海市肺科医院)

摘要号：OA12.01

标题：Safety and Efficacy of QLC1101 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS G12D Mutation

中文标题：QLC1101治疗KRAS G12D突变晚期NSCLC的安全性与疗效

讲者：熊安稳 (同济大学附属东方医院)

摘要号：OA12.02

标题：Efficacy and Safety of HS-10370 Combined With Adebrelimab and Chemotherapy in First-Line Advanced KRAS G12C-Mutated NSCLC

中文标题：HS-10370联合阿得贝利单抗及化疗一线治疗晚期KRAS G12C突变型NSCLC的疗效与安全性

讲者：童凡 (华中科技大学同济医学院附属协和医院)

摘要号：OA12.03

标题：A Single-Arm Phase 2 Study of First-Line Amivantamab, Lazertinib, Pemetrexed in EGFR-mutant NSCLC: AMIGO-1 (LACOG 0821)

中文标题：一线埃万妥单抗+拉泽替尼+培美曲塞治疗EGFR突变型NSCLC的单臂II期研究：AMIGO-1（LACOG 0821）

讲者：William William Jr. (SAO PAULO, Brazil)

摘要号：OA13.01

标题：Intracranial Responders in Cerebrospinal Fluid and Peripheral-Intracranial Immune Linkage During ICI Therapy in NSCLC Brain Metastases

中文标题：NSCLC脑转移免疫检查点抑制剂治疗中脑脊液颅内应答者与外周-颅内免疫联动

讲者：黎扬斯 (广东省人民医院)

摘要号：OA13.02

标题：Spatial Transcriptomic and Proteomic Mapping of TROP2 in NSCLC Reveal RNA-protein Discordance and Tumor Microenvironment Associations

中文标题：NSCLC中TROP2的空间转录组与蛋白组图谱揭示RNA-蛋白不一致性及肿瘤微环境关联

讲者：Jessy Deshane (Delaware, United States of America)

摘要号：OA13.03

标题：Extrachromosomal Circular DNA-mediated Evolution in EGFR-mutated Lung Cancer

中文标题：染色体外环状DNA介导EGFR突变型肺癌的进化

讲者：Jake Lee (New York, United States of America)

摘要号：OA13.04

标题：Pre-Clinical Characterization of IDP-001, a First-in-Class EGFRxCDCP1 Bispecific Antibody Drug Conjugate for Lung Cancer

中文标题：首创EGFR×CDCP1双特异性抗体偶联药物IDP-001治疗肺癌的临床前特征

讲者：Pamela Holland (Seattle, United States of America)

摘要号：OA14.01

标题：RC148 (ABBV-1480, PD-1/VEGF Bispecific Antibody) Plus Chemotherapy in First-Line Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

中文标题：RC148（ABBV-1480，PD-1/VEGF双特异性抗体）联合化疗一线治疗局部晚期或转移性NSCLC

讲者：张力 (中山大学肿瘤防治中心)

摘要号：MO01.01

标题：IL-1ß-Driven Inflammatory Networks Define Stage-Specific Vulnerabilities and Inform Lung Precancer Interception

中文标题：IL-1β驱动的炎症网络界定肺癌前病变的分期特异性脆弱点并为干预拦截提供依据

讲者：Jianjun Zhang (Houston, United States of America)

摘要号：MO01.02

标题：SPP1⁺ Macrophage Niches Define Divergent NK Cell States Associated With Response to Neoadjuvant Immunotherapy in NSCLC

中文标题：SPP1⁺巨噬细胞生态位界定与NSCLC新辅助免疫治疗应答相关的NK细胞分化状态

讲者：Zhenshan Zhang (上海市肺科医院）

摘要号：MO01.03

标题：A Novel De Novo Engineered SFRP2/PDL1 Bispecific Antibody Boosts the Abscopal Effect of Radioimmunotherapy

中文标题：新型从头设计的SFRP2/PD-L1双特异性抗体增强放疗联合免疫治疗的远隔效应

讲者：张艳培 (南方医科大学南方医院)

摘要号：MO01.04

标题：Lung-Targeted mRNA-LNP Delivery of SOX2 Bioprotac: A Comprehensive Strategy for LUAD, LUSC, and SCLC in Monotherapy and Combination Settings

中文标题：肺靶向mRNA-LNP递送SOX2生物蛋白降解剂：单药及联合治疗LUAD、LUSC与SCLC的综合策略

讲者：Jaehyun Choi (Seoul, Korea)

摘要号：MO01.05

标题：mSWI/SNF Complex Inhibition Sensitizes KRAS-Mutant Lung Cancers to Targeted Therapies via Epithelial-Mesenchymal Subversion

中文标题：抑制mSWI/SNF复合物通过逆转上皮-间质转化使KRAS突变型肺癌对靶向治疗增敏

讲者：William Feng (Chevy Chase, United States of America)

摘要号：MO01.06

标题：Multiomic Spatial Analysis Reveals Immunosuppression During Therapy Resistance and Histological Transformation in EGFR-mutant LUAD

中文标题：多组学空间分析揭示EGFR突变型肺腺癌治疗耐药与组织学转化过程中的免疫抑制

讲者：Triparna Sen (Columbus, United States of America)

摘要号：MO01.07

标题：Organoids From Ground-Glass Opacity Reveal a PRO-Invasive Role of THBS2? Cafs in Early-Stage Lung Adenocarcinoma

中文标题：磨玻璃影来源类器官揭示THBS2⁺癌相关成纤维细胞在早期肺腺癌中的促侵袭作用

讲者：Yin Li (上海交通大学)

摘要号：MO01.08

标题：Association of Gut Microbiome Diversity With Survival and Immune-Related Toxicity in Locally Advanced NSCLC

中文标题：肠道微生物组多样性与局部晚期NSCLC生存及免疫相关毒性的关联

讲者：Ana San Martín (Madrid, Spain)

摘要号：MO01.09

标题：Cerebrospinal Fluid Biomarker Profiling in Patients With Non-Small Cell Lung Cancer and Leptomeningeal Disease

中文标题：NSCLC伴软脑膜转移患者的脑脊液生物标志物谱分析

讲者：Mark Jeng (New York, United States of America)

摘要号：MO02.01

标题：Extended CT Surveillance Beyond 5 Years and Outcomes in Long-Term Lung Cancer Survivors

中文标题：长期肺癌生存者5年以上延长CT监测及其结局

讲者：Dong Woog Yoon (Seoul, Korea)

摘要号：MO02.02

标题：A Cross-Sectional Evaluation of Guideline-Adherent Screening Eligibility Among Zimbabwean Lung Cancer Patients

中文标题：津巴布韦肺癌患者符合指南筛查资格的横断面评估

讲者：Tinashe Mazhindu (Harare, Zimbabwe)

摘要号：MO02.03

标题：California Lung Cancer Screening Trial: Female Asian Never-Smokers With a Family History of Lung Cancer

中文标题：加利福尼亚肺癌筛查试验：有肺癌家族史、从不吸烟的亚裔女性

讲者：Michael Ou (San Francisco, United States of America)

摘要号：MO02.04

标题：Real-World Patterns of Care and Outcomes in Second Primary Lung Cancer

中文标题：第二原发肺癌的真实世界诊疗模式与结局

讲者：Qian Wang (New York, United States of America)

摘要号：MO02.05

标题：LET’S SCREEN: Identifying Unmet Social Needs in Patients With Non-Small Cell Lung Cancer

中文标题：LET'S SCREEN研究：识别NSCLC患者未被满足的社会需求

讲者：Ana Velazquez Manana (San Francisco, United States of America)

摘要号：MO02.06

标题：Ambulatory Acute Care in Lung Cancer: Experience From a Palliative Care Day Hospital in Colombia

中文标题：肺癌门诊急症照护：哥伦比亚一家姑息治疗日间医院的经验

讲者：Maria Uchima-Vera (Bogotá, Colombia)

摘要号：MO02.07

标题：From Implementation to Impact: Outcomes of a Nurse-Led Geriatric Oncology Model of Care (NL-GOMOC).

中文标题：从实施到影响：护士主导的老年肿瘤照护模式（NL-GOMOC）的结局

讲者：Nicole Knox (Liverpool, Australia)

摘要号：MO02.08

标题：Age =80 Is Not a Contraindication to Lung Cancer Treatment: Outcomes in a National VA Cohort

中文标题：年龄≥80岁并非肺癌治疗禁忌证：美国退伍军人事务部全国队列结局

讲者：Irina Veytsman (Washington, United States of America)

摘要号：MO02.09

标题：Barriers to Enrollment to a Clinical Trial for Frail Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

中文标题：晚期NSCLC虚弱患者临床试验入组的障碍

讲者：Noah Osei (New york, United States of America)

摘要号：MO03.01

标题：PTPRD-Driven Neuronal Transdifferentiation Orchestrates an Immunosuppressive Microenvironment in TP53-Mutant NSCLC

中文标题：PTPRD驱动的神经元转分化在TP53突变型NSCLC中构建免疫抑制性微环境

讲者：Xinyi Quan (南方医科大学南方医院)

摘要号：MO03.02

标题：Lymph Node Migratory Dendritic Cells Drive Immunosuppressive Remodeling in Early Non-Small Cell Lung Cancer Through the CCL17-CCR4 Axis

中文标题：淋巴结迁移性树突状细胞通过CCL17-CCR4轴驱动早期NSCLC的免疫抑制性重塑

讲者：Yifan Zhang (天津医科大学总医院)

摘要号：MO03.03

标题：SMARCA4 Deficiency Driving Cancer Stem Cell Transformation Into Pericytes and Mediating Immunotherapy Resistance in Lung Cancer

中文标题：SMARCA4缺失驱动肺癌干细胞向周细胞转化并介导免疫治疗耐药

讲者：Xiaonan Zhang (南方医科大学)

摘要号：MO03.04

标题：SLC40A1+ Macrophages Act as Antigen Presenting Cells in EGFR Mutant Patients Exhibiting Resistance to Tyrosine Kinase Inhibitors.

中文标题：SLC40A1⁺巨噬细胞在EGFR突变TKI耐药患者中发挥抗原提呈细胞作用

讲者：Shuxin Zhu (上海市胸科医院 上海交通大学医学院)

摘要号：MO03.05

标题：Tumor Microenvironment Modeling of LUAD Assembloids Containing IPSC Derived MSC Mediated CAF Heterogeneity

中文标题：含iPSC来源间充质干细胞介导CAF异质性的LUAD组装体肿瘤微环境建模

讲者：süleyman günes (Ankara, Turkey)

摘要号：MO03.06

标题：Mechanisms of RBM10-Mediated Metabolic-Immune Crosstalk Inbrain Metastasis of EGFR-Mutant Lung Adenocarcinoma

中文标题：RBM10介导EGFR突变型肺腺癌脑转移中代谢-免疫交互作用的机制

讲者：Jie Liu (哈尔滨医科大学附属肿瘤医院)

摘要号：MO03.07

标题：GRHL3-Mediated Histone Lactylation Compromises the Blood-Brain Barrier and Facilitates Brain Metastasis in Lung Adenocarcinoma

中文标题：GRHL3介导的组蛋白乳酸化破坏血脑屏障并促进肺腺癌脑转移

讲者：Zedong Sun (南京医科大学)

摘要号：MO03.08

标题：Lung-Targeted Nebulized CXCL10 mRNA Nanoparticles Enhance CAR-T Therapy in Lung Cancer

中文标题：肺靶向雾化CXCL10 mRNA纳米颗粒增强肺癌CAR-T细胞治疗效果

讲者：Bufan Xiao (北京大学肿瘤医院)

摘要号：MO03.09

标题：An Atlas of Early Stage ALK+ Lung Adenocarcinoma Reveals a Human-Specific Respiratory Bronchiole Progenitor Signature and Niche Remodeling

中文标题：早期ALK阳性肺腺癌图谱揭示人类特异的呼吸性细支气管祖细胞特征与生态位重塑

讲者：Yusoo Lee (Ann Arbor, United States of America)

摘要号：MO04.01

标题：Prognostic Impact of Stage, Histology, and Treatment Strategy in 1.026 Thymic Epithelial Tumors: Report From Thetyme Registry

中文标题：1026例胸腺上皮肿瘤分期、组织学类型与治疗策略的预后影响：TYME登记研究报告

讲者：Monica Ganzinelli (Padova, Italy)

摘要号：MO04.02

标题：Relevent Trial: Updated Survival Outcomes of Ramucirumab in Combination With Chemotherapy in Untreated Advanced Thymic Carcinoma

中文标题：RELEVENT试验：雷莫芦单抗联合化疗一线治疗晚期胸腺癌的最新生存结局

讲者：Claudia Proto (Milan, Italy)

摘要号：MO04.03

标题：Spatial Transcriptomics Reveals the Potential Mechanism Promoting Immune Exclusion and Chemoresistance in Thymic Carcinoma

中文标题：空间转录组学揭示胸腺癌免疫排斥与化疗耐药的潜在机制

讲者：Yi-Ting Yen (台湾成功大学医学院附属医院)

摘要号：MO04.04

标题：Investigating the Diagnostic and Disease Status Monitoring Potential of Circular RNA Biomarkers for Pleural Mesothelioma

中文标题：环状RNA生物标志物在胸膜间皮瘤诊断与疾病状态监测中的潜力探索

讲者：Ben Johnson (Sydney, Australia)

摘要号：MO04.05

标题：Enriched Germline Variants in Patients With Mesothelioma Identified by Whole Exome Sequencing in a Cohort of 336 Individuals

中文标题：336人间皮瘤队列全外显子组测序鉴定出富集的胚系变异

讲者：Alexander Burdzy (Chicago, United States of America)

摘要号：MO04.06

标题：Multi-Platform ctDNA Profiling in Mesothelioma Reveals Superior Detection With a Whole-Genome Informed Approach

中文标题：间皮瘤多平台ctDNA分析显示全基因组指导策略具有更优检出能力

讲者：Shohei Waller (Melbourne, Australia)

摘要号：MO04.07

标题：Phase II Study of Perioperative Pembrolizumab Plus Neoadjuvant Platinum-Pemetrexed in Resectable Pleural Mesothelioma (CHIMERA Study)

中文标题：围手术期帕博利珠单抗联合新辅助铂类+培美曲塞治疗可切除胸膜间皮瘤的II期研究（CHIMERA研究）

讲者：Giulia Pasello (Padova, Italy)

摘要号：MO04.08

标题：Tumour Extrinsic Regulation of Neutrophils Sensitize Mesotheliomas to AXL and PD1 Inhibition inMIST3, a Phase II Clinical Trial

中文标题：肿瘤外源性中性粒细胞调控使间皮瘤对AXL和PD-1抑制增敏：II期临床试验MIST3

讲者：Dean Fennell (Leicester, United Kingdom)

摘要号：MO04.09

标题：First-Line Pumitamig (PD-L1 × VEGF-A Bsab) Plus Chemotherapy in Unresectable Malignant Mesothelioma: Long-Term PFS and OS

中文标题：一线Pumitamig（PD-L1×VEGF-A双特异性抗体）联合化疗治疗不可切除恶性间皮瘤：长期PFS与OS

讲者：张良 (吉林省肿瘤医院)

摘要号：MO05.01

标题：Clinicopathologic Characteristics and Histologic Transformation of RB1-Mutant Lung Adenocarcinoma

中文标题：RB1突变型肺腺癌的临床病理特征与组织学转化

讲者：赵瑞英 (上海市胸科医院 上海交通大学医学院)

摘要号：MO05.02

标题：Clinical, Pathologic, and Genomic Characteristics of NRAS- or HRAS-Mutant Non-Small Cell Lung Cancer

中文标题：NRAS或HRAS突变型NSCLC的临床、病理与基因组特征

讲者：Can Cui (New York, United States of America)

摘要号：MO05.03

标题：Analysis of MTAP Loss Prevalence Between Tissue and Liquid Non-Small Cell Lung Carcinoma Biopsies

中文标题：NSCLC组织活检与液体活检中MTAP缺失发生率的对比分析

讲者：Christian Rolfo (Columbus, United States of America)

摘要号：MO05.04

标题：A Grading System for Invasive Mucinous Adenocarcinoma of the Lung: A Multi-Institutional Study by the IASLC Pathology Committee

中文标题：肺浸润性黏液腺癌分级系统：IASLC病理委员会多机构研究

讲者：Takuo Hayashi (Tokyo, Japan)

摘要号：MO05.05

标题：The 2025 IASLC Tumor Budding Grade Identifies High-Risk Patients and Predicts Adjuvant Chemotherapy Benefit in Resected Lung SqCC

中文标题：2025 IASLC肿瘤出芽分级识别已切除肺鳞癌高危患者并预测辅助化疗获益

讲者：Tae Hee Hong (Seoul, Korea)

摘要号：MO05.06

标题：Risk Stratification and Surgical Optimization in Lung Adenocarcinoma: Implications of IASLC Grading and Molecular Profiles

中文标题：肺腺癌风险分层与手术优化：IASLC分级与分子特征的意义

讲者：Haojie Si (上海市肺科医院)

摘要号：MO05.07

标题：KRAS G12C Predicts Superior Outcomes With 1L Cemiplimab for Non-Squamous Ansclc With PD-L1 =50%: Data From EMPOWER-Lung 1

中文标题：KRAS G12C预示PD-L1≥50%非鳞NSCLC一线Cemiplimab治疗结局更优：EMPOWER-Lung 1研究数据

讲者：David Gandara (Sacramento, United States of America)

摘要号：MO05.08

标题：Tertiary Lymphoid Structures After Perioperative Chemoimmunotherapy Are Associated With Reduced Disease Progression in NSCLC

中文标题：NSCLC围手术期化疗免疫治疗后形成的三级淋巴结构与疾病进展风险降低相关

讲者：Ángeles Gil-González (Madrid, Spain)

摘要号：MO05.09

标题：Impact of Protein Arginine Methyltransferase 5 (PRMT5) Expression and MTAP Deletion on OS and Immune Cells in NSCLC

中文标题：PRMT5表达与MTAP缺失对NSCLC总生存及免疫细胞的影响

讲者：Robert Hsu (Los Angeles, United States of America)

摘要号：MO06.01

标题：NAUTIKA1: Primary Analysis of Neoadjuvant Alectinib in Resectable Stage IB-IIIB ALK+ NSCLC

中文标题：NAUTIKA1研究：新辅助阿来替尼治疗可切除IB–IIIB期ALK阳性NSCLC的主要分析

讲者：Jay Lee (LOS ANGELES, United States of America)

摘要号：MO06.02

标题：Firmonertinib for Stage I EGFR-Mutated NSCLC With Multiple Primary Lung Cancer: A Phase II Trial

中文标题：伏美替尼治疗I期EGFR突变型NSCLC合并多原发肺癌：II期临床试验

讲者：王烨 (南京医科大学附属肿瘤医院 )

摘要号：MO06.03

标题：Neoadjuvant BNT116 + Cemiplimab + Carboplatin + Paclitaxel in Resectable NSCLC: Preliminary Results From a Phase I Trial

中文标题：新辅助BNT116+Cemiplimab+卡铂+紫杉醇治疗可切除NSCLC：I期试验初步结果

讲者：Rafal Dziadziuszko (Gdansk, Poland)

摘要号：MO06.04

标题：Neoadjuvant Chemo-Immunotherapy vs EGFR-TKI in EGFR-Mutant NSCLC: TP53 as the Predictive Biomarker for Treatment Selection

中文标题：EGFR突变型NSCLC新辅助化疗免疫治疗对比EGFR-TKI：TP53作为治疗选择的预测性生物标志物

讲者：王斐 (广东省人民医院)

摘要号：MO06.05

标题：Role of Multimodal Prehabilitation in Promoting Anti-Tumor Immunity in Lung Cancer

中文标题：多模式术前康复在促进肺癌抗肿瘤免疫中的作用

讲者：Benjamin Gordon (Montreal, Canada)

摘要号：MO06.06

标题：Station-Based Nodal Assessment and Prognosis After Neoadjuvant Immunochemotherapy in Resectable NSCLC

中文标题：可切除NSCLC新辅助免疫化疗后基于淋巴结分站的评估与预后

讲者：钟秋 (广州医科大学)

摘要号：MO06.07

标题：The DUMAS Trial, Neo-Adjuvant Immunotherapy for Pancoast Tumors

中文标题：DUMAS试验：肺上沟瘤（Pancoast瘤）的新辅助免疫治疗

讲者：Mariano Provencio (Majadahonda, Spain)

摘要号：MO06.08

标题：Long-Term Outcomes Following Neoadjuvant SBRT Combined With Immunochemotherapy in Stage II-III NSCLC

中文标题：II–III期NSCLC新辅助SBRT联合免疫化疗的长期结局

讲者：杨弘 (中山大学肿瘤防治中心)

摘要号：MO06.09

标题：Role of PET/CT in the Neoadjuvant Chemoimmunotherapy Approach for Resectable NSCLC: Results From the NADIM II and REAL-NADIM Trials

中文标题：PET/CT在可切除NSCLC新辅助化疗免疫治疗中的作用：NADIM II与REAL-NADIM试验结果

讲者：Aylen Ospina Serrano (Madrid, Spain)

摘要号：MO07.01

标题：Development of a Shared Neoantigen Peptide Library to Promote Personalized Vaccine Strategy in Patients With Non-Small Cell Lung Cancer

中文标题：构建共享新抗原肽库以推动NSCLC患者个体化疫苗策略

讲者：Fangjun Chen (南京大学医学院附属鼓楼医院)

摘要号：MO07.02

标题：Characteristics and Outcomes to Immunotherapy in Patients With NSCLC Harboring Class II and III BRAF Alterations

中文标题：携带II类和III类BRAF变异的NSCLC患者特征及免疫治疗结局

讲者：Alessandro Di Federico (Bologna, Italy)

摘要号：MO07.03

标题：Biallelic Inactivation of KEAP1/STK11 Predicts Benefit to Dual PD-(l)1/CTLA4 Immune Checkpoint Blockade in Non-Small Cell Lung Cancers

中文标题：KEAP1/STK11双等位基因失活预测NSCLC从PD-(L)1/CTLA-4双重免疫检查点阻断中获益

讲者：Mark Jeng (New York, United States of America)

摘要号：MO07.04

标题：Gotistobart vs Docetaxel in Metastatic Squamous NSCLC After PD-(l)1 Progression: Updated Overall Survival of the stage 1 of PRESERVE-003

中文标题：PD-(L)1抑制剂进展后转移性肺鳞癌中Gotistobart对比多西他赛：PRESERVE-003研究第一阶段更新的总生存数据

讲者：Rama Balaraman (Orlando, United States of America)

摘要号：MO07.05

标题：Phase 2 Study of Investigational Agents Plus Tislelizumab ± Chemotherapy in Untreated Locally Advanced/Metastatic NSCLC

中文标题：在研药物联合替雷利珠单抗±化疗一线治疗局部晚期/转移性NSCLC的II期研究

讲者：George Blumenschein, Jr (Houston, United States of America)

摘要号：MO07.06

标题：Phase II Study of Opamtistomig (LBL-024), a PD-L1/4-1BB Bispecific Antibody Plus Chemotherapy in First-Line Advanced NSCLC

中文标题：PD-L1/4-1BB双特异性抗体Opamtistomig（LBL-024）联合化疗一线治疗晚期NSCLC的II期研究

讲者：黄岩 (中山大学肿瘤防治中心)

摘要号：MO07.07

标题：First-in-Human Study of HC010, a Novel PD-1/VEGF/CTLA-4 Trispecific Antibody: Preliminary Results

中文标题：新型PD-1/VEGF/CTLA-4三特异性抗体HC010的首次人体研究：初步结果

讲者：马宇翔 (中山大学肿瘤防治中心)

摘要号：MO07.08

标题：Balancing Efficacy and Toxicity in NSCLC Immunotherapy: Multimodal Artificial Intelligence Framework for Dual-Outcome Risk Stratification

中文标题：平衡NSCLC免疫治疗的疗效与毒性：用于双重结局风险分层的多模态人工智能框架

讲者：丁瀚林 (南京医科大学附属肿瘤医院)

摘要号：MO07.09

标题：Peripheral Blood PD-1+ Tfh Cells Predict Response and Survival to PD-1 Blockade in Lung Adenocarcinoma

中文标题：外周血PD-1⁺ Tfh细胞预测肺腺癌PD-1阻断治疗的应答与生存

讲者：徐燕 (中国医学科学院北京协和医院)

摘要号：MO07.10

标题：Updated Efficacy Results of Rilvegostomig for Checkpoint Inhibitor (CPI)-NaïVe Metastatic Non-Small-Cell Lung Cancer (Mnsclc)

中文标题：Rilvegostomig用于免疫检查点抑制剂初治转移性NSCLC的最新疗效结果

讲者：Byoung Chul Cho (Seoul, Korea)

摘要号：MO08.01

标题：Randomized Trial of a Self-Management Intervention for Patient-Caregiver Dyads in Lung Cancer Surgery

中文标题：肺癌手术患者-照护者二元自我管理干预的随机试验

讲者：Jae Kim (Duarte, United States of America)

摘要号：MO08.02

标题：Construction and Application of an Empowerment Theory-Based Intervention Program for Learned Helplessness in Elderly Patients With Lung Cancer

中文标题：基于赋能理论的老年肺癌患者习得性无助干预方案的构建与应用

讲者：JunLin Hu (重庆大学附属肿瘤医院)

摘要号：MO08.03

标题：Parallel Stress, Divergent Outcomes: Patient and Caregiver Psychological Distress Following Lung Cancer Surgery

中文标题：平行压力、不同结局：肺癌术后患者与照护者的心理痛苦

讲者：Dede Teteh-Brooks (Loma Linda, United States of America)

摘要号：MO08.04

标题：Implementing Scalable Exercise in Lung Cancer Care: Late-Breaking Results From the Randomized Lungfit Crossover Trial

中文标题：在肺癌照护中实施可推广的运动干预：随机Lungfit交叉试验最新结果

讲者：Enric Carcereny (Barcelona, Spain)

摘要号：MO08.05

标题：Community-Based Exercise in Advanced NSCLC: Quality of Life and Biomarker Outcomes From the PRO-ACTIVATE Multicenter Study

中文标题：晚期NSCLC的社区运动干预：PRO-ACTIVATE多中心研究的生活质量与生物标志物结局

讲者：Oliver Higuera (Zaragoza, Spain)

摘要号：MO08.06

标题：ROAR-LCT: Implementation and Process Evaluation of a Multimodal Virtual Health Intervention for Older Adults With Advanced Thoracic Cancer

中文标题：ROAR-LCT：晚期胸部肿瘤老年患者多模态虚拟健康干预的实施与过程评价

讲者：Carolyn Presley (Columbus, United States of America)

摘要号：MO08.07

标题：In-Hospital ePRO-Based Symptom Management and Functional Recovery After Lung Cancer Surgery: A Secondary Analysis of a Randomized Trial

中文标题：基于ePRO的住院期症状管理与肺癌术后功能恢复：一项随机试验的二次分析

讲者：Yadi Zhang (四川省肿瘤医院)

摘要号：MO08.08

标题：Temporal Timing of Iraes Modulates Anti-PD-L1 Efficacy-Toxicity Association in Adjuvant and Advanced Treatment of NSCLC

中文标题：irAE发生时间对NSCLC辅助及晚期治疗中抗PD-L1疗效-毒性关联的调节作用

讲者：Ning Gao (中山大学附属第一医院)

摘要号：MO08.09

标题：Paclitaxel-Induced Neuropathy Prevention With Goshajinkigan in a Lung Cancer-Predominant Population: OLCSG2101 Randomized Phase II Trial

中文标题：牛车肾气丸预防紫杉醇所致周围神经病变（以肺癌人群为主）：OLCSG2101随机II期试验

讲者：Takaaki TANAKA (Okayama, Japan)

摘要号：MO09.01

标题：Concurrent or Consolidative Cranial Stereotactic Radiotherapy in Osimertinib-Treated NSCLC With Limited Brain Metastases

中文标题：奥希替尼治疗伴有限脑转移NSCLC的同期或巩固性颅内立体定向放疗

讲者：朱正飞 (复旦大学附属肿瘤医院)

摘要号：MO09.02

标题：Intracranial Tumour Kinetics in EGFRm NSCLC Treated With Osimertinib, With or Without Upfront Stereotactic Radiosurgery: A STARLET Analysis

中文标题：奥希替尼±先行立体定向放射外科治疗EGFR突变型NSCLC的颅内肿瘤动力学：STARLET分析

讲者：Cheryl Ho (Vancouver, Canada)

摘要号：MO09.03

标题：Health Related Quality of Life in EGFR-mutated Lung Cancer With Brain Metastases: A Joint Analysis of LUOSICNS and OUTRUN Randomised Trials

中文标题：EGFR突变型肺癌脑转移患者的健康相关生活质量：LUOSICNS与OUTRUN随机试验联合分析

讲者：Yu Yang Soon (Singapore, Singapore)

摘要号：MO09.04

标题：Health-Related Quality of Life With Tumor Treating Fields (Ttfields) Therapy Added to Systemic Therapy in Metastatic NSCLC

中文标题：肿瘤电场治疗（TTFields）联合系统治疗转移性NSCLC的健康相关生活质量

讲者：Rupesh Kotecha (Miami, United States of America)

摘要号：MO09.05

标题：Improved Survival and Disease Control: HITOC Combined With Targeted Therapy in Advanced Lung Adenocarcinoma With MPE

中文标题：改善生存与疾病控制：胸腔热灌注化疗（HITOC）联合靶向治疗合并恶性胸腔积液的晚期肺腺癌

讲者：罗志林 (重庆医科大学附属第三医院)

摘要号：MO09.06

标题：Impact of New-Lesion Progression Risk on Survival Benefit of Local Consolidative Therapy in Immunotherapy-Treated Ansclc

中文标题：新病灶进展风险对免疫治疗晚期NSCLC局部巩固治疗生存获益的影响

讲者：Hongru Chen (复旦大学附属肿瘤医院)

摘要号：MO09.07

标题：Surgery Versus Continued ALK-TKI Therapy Alone in Stage IV ALK-Positive NSCLC: A Propensity Score-Matched Retrospective Study

中文标题：IV期ALK阳性NSCLC手术对比继续单纯ALK-TKI治疗：倾向评分匹配回顾性研究

讲者：李泽立 (广东省人民医院)

摘要号：MO09.08

标题：Double Lung Transplantation in Patients With Metastatic Lung-Limited Non-Small Cell Lung Carcinoma (NSCLC): A Case Series

中文标题：双肺移植治疗局限于肺内转移的NSCLC：病例系列

讲者：Young Chae (Chicago, United States of America)

摘要号：MO09.09

标题：Thoracic Radiotherapy Exposure and Subsequent Risk of Immune Checkpoint Inhibitor Pneumonitis (ICI-P)

中文标题：胸部放疗暴露与后续免疫检查点抑制剂肺炎（ICI-P）风险

讲者：Elio Adib, Resident (New Haven, United States of America)

摘要号：MO10.01

标题：Beyond Smoking: Evaluating Environmental Risk Factors and Lung Cancer Screening Eligibility in Central Asia

中文标题：超越吸烟：中亚地区肺癌环境危险因素与筛查资格评估

讲者：Emanuela Taioli (New York, United States of America)

摘要号：MO10.02

标题：Long-Term PM2.5 Exposure and Lung Cancer-Specific Mortality in Patients Who Have Never Smoked Across Two Healthcare Systems

中文标题：两大医疗体系中从不吸烟者的长期PM2.5暴露与肺癌特异性死亡率

讲者：Tae Yoon Lee (Stanford, United States of America)

摘要号：MO10.03

标题：Socioeconomic Disparities in Lung Cancer Burden and Radon Testing Across Michigan Counties

中文标题：密歇根州各县肺癌负担与氡检测的社会经济差异

讲者：Kaitlin Driesse-Keegan (East Lansing, United States of America)

摘要号：MO10.04

标题：Impact of Driver Mutations on Survival of Never-Smokers With Lung Cancer: Insights From the Largest Cohort in Europe

中文标题：驱动突变对不吸烟肺癌患者生存的影响：欧洲最大队列的启示

讲者：Sindhu Naidu (London, United Kingdom)

摘要号：MO10.05

标题：One Mutation, Many Fates: Multi-Region Molecular Profiling Decodes Divergent Trajectories in EGFR-Mutant Never-Smoker Lung Cancer

中文标题：一种突变、多种转归：多区域分子分型解码EGFR突变不吸烟肺癌的不同演进轨迹

讲者：Komal Gupta (singapore, Singapore)

摘要号：MO10.06

标题：National Lung Cancer Incidence Among U.S. Persons Who Have Never Smoked

中文标题：美国从不吸烟人群的全国肺癌发病率

讲者：Deepti Srinivasan (Boston, United States of America)

摘要号：MO10.07

标题：Lung Cancer in Women in the MENA Region: An Epidemiologic Shift, a GLOBOCAN-Based Longitudinal Study (2012-2022)

中文标题：中东北非地区女性肺癌的流行病学转变：基于GLOBOCAN的纵向研究（2012–2022）

讲者：K.H. Al-rabi (amman, Jordan)

摘要号：MO10.08

标题：Female Sex Is Associated With Improved Survival in ALK-Positive NSCLC: Individual Pooled Data Analysis From Phase 3 Rcts

中文标题：女性性别与ALK阳性NSCLC生存改善相关：III期随机对照试验个体数据汇总分析

讲者：Hui Jing Hoe (Melbourne, Australia)

摘要号：MO10.09

标题：ATRX Mutations Are Enriched in Female NSCLC and Associated With Higher Tumor Mutational Burden

中文标题：ATRX突变在女性NSCLC中富集并与更高肿瘤突变负荷相关

讲者：Victor Lee (New Haven, United States of America)

摘要号：MO11.01

标题：Deep Driver Mutation Analysis, with/without TP53 in LUAD Using Next-Gen AI of HE Slide-Derived Morphology

中文标题：基于新一代人工智能的HE切片形态学分析LUAD驱动突变及TP53共突变状态

讲者：Bide Zhang (Cologne, Germany)

摘要号：MO11.03

标题：Whole-Transcriptome Profiling for the Prediction of Metastatic Recurrence in Patients With Early-Stage Non-Small Cell Lung Cancer

中文标题：全转录组分析预测早期NSCLC患者转移性复发

讲者：Roberto Borea (Buenos Aires, Argentina)

摘要号：MO11.05

标题：Enhanced Detection of Actionable Fusions in NSCLC Using Combined ctDNA and ctRNA Analysis

中文标题：ctDNA联合ctRNA分析提升NSCLC可干预融合变异的检出率

讲者：Chinmay Jani (Doral, United States of America)

摘要号：MO11.06

标题：Nanovesicle Conversion and Multivalent Sensing Enable Sensitive Liquid Biopsy by Overcoming CTC Rarity and Heterogeneity in Lung Cancer

中文标题：纳米囊泡转化与多价传感克服CTC稀有性与异质性，实现肺癌高灵敏液体活检

讲者：SunWoo Hong (Incheon, Korea)

摘要号：MO11.07

标题：Integrated Analysis of Lung Microbiome Predicts Response to Anti-PD-1/PD-L1 Immunotherapy in Patients With Non-Small Cell Lung Cancer

中文标题：肺微生物组整合分析预测NSCLC患者抗PD-1/PD-L1免疫治疗应答

讲者：Lv Wu (广东省人民医院)

摘要号：MO11.08

标题：Beyond PCR: Prognostic Biomarkers in Non-pCR Patients After Neoadjuvant Chemoimmunotherapy for Potentially Resectable Stage IIIA/IIIB NSCLC

中文标题：超越pCR：潜在可切除IIIA/IIIB期NSCLC新辅助化疗免疫治疗后未达pCR患者的预后生物标志物

讲者：孙超 (吉林大学第一医院)

摘要号：MO11.09

标题：Post-Surgical Molecular Residual Disease Detection, Adjuvant Treatment Patterns, and Overall Survival in Resected Stage I-III NSCLC

中文标题：已切除I–III期NSCLC术后分子残留病灶（MRD）检测、辅助治疗模式与总生存

讲者：Charu Aggarwal (Philadelphia, United States of America)

摘要号：MO12.01

标题：Safety, Pharmacokinetics, and Preliminary Antitumor Activity of VRN110755 in EGFR-Mutated NSCLC

中文标题：VRN110755治疗EGFR突变型NSCLC的安全性、药代动力学与初步抗肿瘤活性

讲者：Myung-Ju Ahn (Seoul, Korea)

摘要号：MO12.02

标题：Anti-Tumor Activity of BH-30643, a Novel Macrocyclic EGFR TKI, in Patients With Secondary EGFR Resistance Mutations

中文标题：新型大环EGFR-TKI BH-30643在继发EGFR耐药突变患者中的抗肿瘤活性

讲者：Hidehito Horinouchi (Tokyo, Japan)

摘要号：MO12.03

标题：Long-Term Safety of Lorlatinib After 7 Years in CROWN: Kinetics, Management, and Correlations With Efficacy

中文标题：CROWN研究7年随访：洛拉替尼长期安全性的时间动态、管理及其与疗效的相关性

讲者：Geoffrey Liu (Toronto, Canada)

摘要号：MO12.04

标题：Molecular Landscape of Acquired Resistance to Sevabertinib in HER2-mutant NSCLC: Exploratory Biomarker Analysis of SOHO-01

中文标题：HER2突变型NSCLC对Sevabertinib获得性耐药的分子图谱：SOHO-01探索性生物标志物分析

讲者：Xiuning Le (Houston, United States of America)

摘要号：MO12.05

标题：Acquired Resistance to Zongertinib Treatment in Patients With HER2-Mutant NSCLC: Phase Ib Beamion LUNG-1 Study

中文标题：HER2突变型NSCLC患者对Zongertinib的获得性耐药：Ib期Beamion LUNG-1研究

讲者：David Planchard (France)

摘要号：MO12.06

标题：Ivonescimab Plus Chemotherapy for Refractory Leptomeningeal Metastasis After High-Dose EGFR-TKI Failure in EGFR-Mutated NSCLC

中文标题：依沃西单抗联合化疗治疗EGFR突变型NSCLC大剂量EGFR-TKI失败后的难治性软脑膜转移

讲者：李晓燕 (首都医科大学附属北京天坛医院)

摘要号：MO12.07

标题：160Mgfurmonertinib for EGFR-Mutated NSCLC With Leptomeningeal Metastases: A Prospective Single-Arm Study

中文标题：160 mg伏美替尼治疗EGFR突变型NSCLC软脑膜转移：前瞻性单臂研究

讲者：Yuehong Wang (浙江大学医学院附属第一医院)

摘要号：MO12.08

标题：A Pivotal Phase II Study of Ficonalkib, a 3rd-Generation ALK-TKI, in Advanced ALK-Positive NSCLC After 2nd-Generation ALK-TKI Failure

中文标题：第三代ALK-TKI Ficonalkib治疗二代ALK-TKI失败的晚期ALK阳性NSCLC的关键II期研究

讲者：石远凯 (中国医学科学院肿瘤医院)

摘要号：MO12.09

标题：Subcutaneous Amivantamab+Lazertinib With Supportive Care in EGFRm NSCLC: Longer Follow-Up From the Pragmatic COPERNICUS Study

中文标题：皮下注射埃万妥单抗+拉泽替尼联合支持治疗EGFR突变型NSCLC：实用性COPERNICUS研究更长随访

讲者：Balazs Halmos (Bronx, United States of America)

摘要号：MO13.01

标题：Impact of Immunotherapy Shortage on Survival in Stage IV NSCLC During the Lebanese Economic Crisis

中文标题：黎巴嫩经济危机期间免疫治疗短缺对IV期NSCLC生存的影响

讲者：Arafat Tfayli (Beirut, Lebanon)

摘要号：MO13.02

标题：Global Productivity Losses From Premature Lung Cancer Mortality: A Modeling Study Across 185 Countries

中文标题：肺癌过早死亡导致的全球生产力损失：覆盖185个国家的建模研究

讲者：Natalia Libonati (Kingston, Canada)

摘要号：MO13.03

标题：Simplified Trials, Broader Reach: Lessons From SWOG S2302 Pragmatica-Lung

中文标题：简化试验、扩大覆盖：SWOG S2302 Pragmatica-Lung研究的经验

讲者：Maya Khalil (United States of America)

摘要号：MO13.04

标题：The Somatic and Germline Mutational Landscape in Young- and Average-Onset Non-Small Cell Lung Cancer (NSCLC)

中文标题：早发与平均发病年龄NSCLC的体系与胚系突变图谱

讲者：Katherine Smith (Rochester, United States of America)

摘要号：MO13.05

标题：Real-World Uptake and Outcomes of Adjuvant Osimertinib in EGFR-mutated NSCLC and Impact of TP53 Co-Mutations

中文标题：EGFR突变型NSCLC辅助奥希替尼的真实世界应用与结局及TP53共突变的影响

讲者：Stephanie Saw (Singapore, Singapore)

摘要号：MO13.06

标题：A Triage-Aware Neuro-Symbolic Platform for Safe Lung Cancer Trial Matching

中文标题：具备分诊感知能力的神经-符号平台用于安全的肺癌临床试验匹配

讲者：vittoria peppoloni (milan, Italy)

摘要号：MO13.07

标题：Accuracy and Safety of AI-generated Summaries in Lung Multidisciplinary Cancer Conferences: A Prospective Pilot Study

中文标题：肺癌多学科诊疗（MDT）会议中AI生成摘要的准确性与安全性：前瞻性初步研究

讲者：Luxiga Thanabalachandran (Kingston, Canada)

摘要号：MO13.08

标题：AI-based Detection of New, Relevant Pulmonary Findings on Radiotherapy Planning CT Scans in Patients With Lung Cancer

中文标题：基于人工智能在肺癌患者放疗定位CT上检测新发相关肺部征象

讲者：Asabi Leliveld (Rotterdam, Netherlands)

摘要号：MO13.09

标题：Prevalence of Immunotherapy (IO) Biomarkers, Tumor Microenvironment (TME) Composition and Survival by Race/Ethnicity in NSCLC

中文标题：NSCLC不同种族/族裔的免疫治疗生物标志物发生率、肿瘤微环境构成与生存

讲者：Robert Hsu (Los Angeles, United States of America)

摘要号：MO14.01

标题：EU-Wide Estimates of the Burden of Lung Cancer, Screening Eligibility and CT-Capacity Needs

中文标题：欧盟范围的肺癌负担、筛查资格与CT设备能力需求估算

讲者：Katarina Bartekova (Rotterdam, Netherlands)

摘要号：MO14.02

标题：When Will Australia See a National NSCLC Stage Shift? Population Modelling of Lung Cancer Screening

中文标题：澳大利亚何时能实现全国NSCLC分期前移？肺癌筛查的人群模型研究

讲者：Yue He (Sydney, Australia)

摘要号：MO14.03

标题：Third Brazilian Early Lung Cancer Trial (BRELT3): Initial Results of Mobile Lung CT Screening in Low Resources Setting

中文标题：第三届巴西早期肺癌试验（BRELT3）：低资源地区移动肺部CT筛查的初步结果

讲者：Ricardo Sales Santos (Salvador Bahia, Brazil)

摘要号：MO14.04

标题：Comparison of Lung Cancer Screening Outcomes Between Family History and Smoking Risks: Results From the TNLCEDP

中文标题：家族史与吸烟风险人群肺癌筛查结局比较：台湾肺癌早期检测项目（TNLCEDP）结果

讲者：Li-Ju Lin (台湾卫生福利部健康促进署)

摘要号：MO14.05

标题：Precision Prevention in Action: Results From the INTERCEPTION-Lung Screening and Prevention Program

中文标题：精准预防实践：INTERCEPTION-Lung筛查与预防项目结果

讲者：Pamela Abdayem (Villejuif, France)

摘要号：MO14.06

标题：Comparison of Sybil Artificial Intelligence With Lung-RADS for Lung Cancer Detection on Low-Dose CT Screening

中文标题：Sybil人工智能与Lung-RADS在低剂量CT筛查肺癌检出中的比较

讲者：Morteza Naghavi (Houston, United States of America)

摘要号：MO14.07

标题：Artificial Intelligence-Based Lung Cancer Risk Prediction From Cardiac CT in Smokers and Non-Smokers: A Heartlung Study Within the MESA Cohort

中文标题：基于心脏CT的人工智能肺癌风险预测（吸烟与不吸烟者）：MESA队列Heartlung研究

讲者：Mohammad Mozafary (Pasadena, United States of America)

摘要号：MO14.08

标题：Artificial Intelligence (AI) Driven Incidental Pulmonary Nodule (IPN) Programs Diagnosed More Lung Cancer Patients Than LDCT Screening.

中文标题：人工智能驱动的偶发肺结节（IPN）管理项目较LDCT筛查诊断出更多肺癌患者

讲者：Luis Raez (doral, United States of America)

摘要号：MO14.09

标题：Mortality Reduction in a Broader High-Risk Population: Results From China Lung Cancer Screening (CLUS) Version 1.0 With 10-Year Follow-Up

中文标题：更广泛高危人群的死亡率降低：中国肺癌筛查（CLUS）1.0版10年随访结果

讲者：钱芳菲 (上海市胸科医院)

摘要号：MO15.01

标题：CXCL9+ DCs and CXCR3+ Tregs Drive Neoadjuvant Chemoimmunotherapy Resistance in Limited-Stage SCLC

中文标题：CXCL9⁺树突状细胞与CXCR3⁺调节性T细胞驱动局限期SCLC新辅助化疗免疫治疗耐药

讲者：王海永 (山东省肿瘤医院)

摘要号：MO15.02

标题：A Phase 2 Trial of QLC5508 (MHB088C) Plus QL1706 or QL2107 as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

中文标题：QLC5508（MHB088C）联合QL1706或QL2107一线治疗广泛期SCLC的II期试验

讲者：Xinru Chen (上海市东方医院)

摘要号：MO15.03

标题：Pathological Response and MRD Dynamics After Neoadjuvant Serplulimab Plus Chemotherapy in Stage IIB-IIIB(N2) LS-SCLC

中文标题：IIB–IIIB（N2）期局限期SCLC新辅助斯鲁利单抗联合化疗后的病理缓解与MRD动态

讲者：陈志勇 (广东省人民医院)

摘要号：MO15.04

标题：First-Line YL201 Plus Serplulimab in ES-SCLC and Advanced NSCLC: Phase 1 Results of a B7-H3-Directed Combination Strategy

中文标题：一线YL201联合斯鲁利单抗治疗广泛期SCLC与晚期NSCLC：B7-H3靶向联合策略的I期结果

讲者：赵洪云 (中山大学肿瘤防治中心)

摘要号：MO15.05

标题：Expression and Prognostic Impact of B7-H3 in Patients With Extensive-Stage Small-Cell Lung Cancer

中文标题：B7-H3在广泛期SCLC患者中的表达及预后影响

讲者：Stephen Liu (Washington, United States of America)

摘要号：MO15.06

标题：Chemoresistant SCLC Shows SLFN11-Driven Vulnerability to Antibody-Drug Conjugates in Combination With ATR Inhibition

中文标题：化疗耐药SCLC呈现SLFN11驱动的对抗体偶联药物联合ATR抑制治疗的易感性

讲者：Karin Schelch (Austria)

摘要号：MO15.07

标题：Subcutaneous (SC) Tarlatamab in Patients W/ Extensive-Stage Small Cell Lung Cancer (ES-SCLC): DeLLphi-308 Ph 1B Study

中文标题：皮下注射塔拉妥单抗治疗广泛期SCLC：DeLLphi-308 Ib期研究

讲者：Pedro Rocha (Barcelona, Spain)

摘要号：MO15.08

标题：Dynamic Granulocyte Turnover Inferred From cfDNA Methylation Predicts Immunotherapy Benefit in Liver-Metastatic Small-Cell Lung Cancer

中文标题：cfDNA甲基化推断的动态粒细胞更新预测肝转移SCLC免疫治疗获益

讲者：王海永 (山东省肿瘤医院)

摘要号：MO15.09

标题：Baseline CT-Derived Imaging Biomarkers Predict Risk of Neurotoxicity and Cytokine Release Syndrome With Tarlatamab in ES-SCLC

中文标题：基线CT影像生物标志物预测塔拉妥单抗治疗ES-SCLC的神经毒性与细胞因子释放综合征风险

讲者：Lukas Delasos, D.O. (Cleveland, United States of America)

摘要号：MO16.01

标题：Optimal Extent of Lymphadenectomy (OL) for Resection of NSCLC in IASLC 9th Edition Database

中文标题：基于IASLC第9版数据库的NSCLC切除最佳淋巴结清扫范围

讲者：Chi-Fu Jeffrey Yang (Winchester, United States of America)

摘要号：MO16.02

标题：Lobe-Specific vs No Mediastinal Lymph Node Dissection in Segmentectomy for Stage I NSCLC: Supplementary Analysis of JCOG1211

中文标题：I期NSCLC肺段切除中肺叶特异性纵隔淋巴结清扫对比不清扫：JCOG1211补充分析

讲者：Ken Onodera (Sendai, Japan)

摘要号：MO16.03

标题：Sleeve Resection vs Pneumonectomy in NSCLC: Survival Benefit by Age, Nodal Status, and Resection Completeness

中文标题：NSCLC袖式切除对比全肺切除：按年龄、淋巴结状态与切除完整性分层的生存获益

讲者：Thomas Schneider (Karlsruhe, Germany)

摘要号：MO16.04

标题：Routine Minimally Invasive Thoracic Surgery Without Aspirin Withdrawal: A Prospective, Single-Center, Single-Arm Phase 2 Clinical Study

中文标题：不停用阿司匹林行常规微创胸外科手术：前瞻性单中心单臂II期临床研究

讲者：赵云鹏 (山东大学齐鲁第二医院)

摘要号：MO16.05

标题：Lobar-Specific Limitations of Surgical Margins After Complex Segmentectomy

中文标题：复杂肺段切除术后手术切缘的肺叶特异性局限

讲者：Tetsuya Isaka (Yokohama, Japan)

摘要号：MO16.06

标题：Margin Benchmark for Adequate Local Control in=2 cm Nodal Negative Invasive Lung Adenocarcinoma Sublobar Resection

中文标题：≤2 cm淋巴结阴性浸润性肺腺癌亚肺叶切除充分局部控制的切缘基准

讲者：Zhizhou Yang (Boston, United States of America)

摘要号：MO16.07

标题：Mutation-Based Risk Stratification and Immunogenomic Features of Nodal Metastasis in Stage T1 Lung Adenocarcinoma

中文标题：T1期肺腺癌淋巴结转移的基于突变的风险分层与免疫基因组特征

讲者：吴芳 (中南大学湘雅二医院)

摘要号：MO16.08

标题：Prognostic Value of the IASLC Grading System in Pathologic Stage I Lung Adenocarcinoma Presenting as Subsolid Nodules

中文标题：IASLC分级系统在表现为亚实性结节的病理I期肺腺癌中的预后价值

讲者：Xinjie Xia (上海市肺科医院)

摘要号：MO16.09

标题：Prognostic Impact of Tumor Centrality and Relationship to Pathologic Aggressiveness in Early NSCLC

中文标题：肿瘤中央型位置对早期NSCLC预后的影响及其与病理侵袭性的关系

讲者：Ji Yong Kim (Seoul, Korea)